WA-PATTERN-COMPUTER
17.6.2021 22:05:07 CEST | Business Wire | Press release
Pattern Computer,® Inc . (PCI) has developed a novel test for near real-time (15 sec) diagnosis of SARS-CoV-2 infections. In contrast with widely used antibody and PCR tests, which take at least 15 minutes to produce results, and require scarce reagents to process, the newly developed PCI method enables high-volume throughput of tests without requiring chemical reagents at difficult to service locations, such as company entrances, event venues, court houses, state and federal facilities, TSA screening areas and ports of entry.
“Having a simple, fast, easy to administer, high accuracy COVID-19 test will be critical for TSA and the airline carriers to increase passenger safety and confidence, as carriers deal with rising passenger loads and increased health security requirements,” said Bob Edwards, former CIO for United Airlines. “Pattern Computer’s new system appears to meet that need.”
Developed using the Pattern Discovery Engine™ (PDE) comprised of proprietary software methods and specially configured hardware, the initial results suggest this low-cost, high-volume COVID-19 test could create new opportunities for reducing transmission risk in high-headcount, high-density entertainment venues, large-scale events, office buildings, trains, busses, aircraft, and subways.
“As the world enters the next cycles of COVID lockdowns and flareups, there will be a pressing need for the companion technology to vaccines – the ability to detect true positive infections, and simultaneously reduce the incidence of false positives, coupled with higher reliability rates, delivered in real time. These are the required characteristics of a regimen of testing that will enable better containment of future outbreaks. The Pattern Computer team was able to apply the proven abilities of the Pattern Discovery Engine to take on this daunting challenge. We wanted to create a high-performance, extremely accurate, reagent-free, real-time alternative for testing in the world’s most important venues. This combination of proprietary hardware and software appears capable of meeting that critical need,” according to Mark R. Anderson, CEO of Pattern Computer.
Pattern Computer’s new test has been used to analyze data from symptomatic and asymptomatic patients between 10 and 80 years old. The reported balanced accuracy of the new test is >96%. The aspects of the testing that are worth noting: the Pattern team has been working on the problem for a few months, and is working with a dataset that numbers in the hundreds of data points. Competing organizations and teams have been working on the same problem for over a year with millions of data points, to only deliver tests that are 97% accurate.
The results from the Pattern tests are competitive with the performance of antibody tests currently in the market, which under ideal conditions (3 weeks after onset of symptoms) reports a balanced accuracy of 95%1 . In contrast to antibody tests, which are highly sensitive to timing--only 30% of people infected with SARS-CoV-2 tests positive 1 week after the onset of symptoms--the performance of PCI diagnosis is agnostic regarding how long the patient has been symptomatic.
“Pattern Computer has rapidly developed a reagent free SARS-CoV-2 diagnostic platform with an impressive level of accuracy. This technology has the potential to alter the landscape of disease diagnostics. Currently, they are focused on COVID-19, but their approach is applicable, in principle, to any disease. I suspect that, in the new future, as we walk through TSA security at an airport, part of the screen will be for infectious diseases. The implications of this technology for public safety and health, especially disease surveillance, are enormous,” said Prof. J. Ben Brown, UC Berkeley & Lawrence Berkeley National Laboratory.
PCI has built an initial model that predicts COVID-19 status (as determined by multi-target RT-PCR) of a patient based on its proprietary hardware measurements. Sensitivity and specificity are computed with 5-fold cross-validation.
PCI expects that as more data points are added to the PCI data base, particularly data from non-infected individuals, its technology will be able to match or exceed RT-PCR for accurate SARS-CoV-2 infection detection, with the reduced result time of 20 seconds rather than the current standard wait time of 30 minutes or more2 .
The foregoing contains statements about the Pattern Computer’s future that are not statements of historical fact. These statements are “forward-looking statements” for purposes of applicable securities laws and are based on current information and/or management's good faith belief as to future events. The words “believe,” “expect,” “anticipate,” “project,” “should,” “could,” “will,” and similar expressions signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance. By their nature, forward-looking statements involve inherent risk and uncertainties, which change over time, and actual performance could differ materially from that anticipated by any forward-looking statements. Pattern Computer undertakes no obligation to update or revise any forward-looking statement.
About Pattern Computer
Pattern Computer, Inc., a Seattle-area startup, uses its proprietary Pattern Discovery Engine to solve the most important and most intractable problems in business and medicine. Its proprietary mathematical techniques can find complex patterns in very-high-order data that have eluded detection by much larger systems.
While the company is currently applying its computational platform to the challenging field of drug discovery, it is also making pattern discoveries for partners in several other sectors, including additional biomedical research, materials science, aerospace manufacturing, veterinary medicine, air traffic operations, and finance.
For more information on Pattern Computer Inc., visit: www.patterncomputer.com
For more information about Mark Anderson, visit: www.patterncomputer.com/founders/
Copyright © 2021 Pattern Computer, Inc. All Rights Reserved. Pattern Computer Inc., and PCI are trademarks of Pattern Computer, Inc. or its subsidiaries. Other trademarks may be trademarks of their respective owners.
_________________________________________________
1
Antibody tests for identification of current and past infection with SARS‐CoV‐2 - Deeks, JJ - 2020 | Cochrane Library
, https://doi.org/10.1002/14651858.CD013652
, June 25, 2020
2
Covid-19: Bosch develops “fastest” PCR test in the world (msn.com)
, https://www.msn.com/en-ae/news/other/covid-19-bosch-develops-fastest-pcr-test-in-the-world/ar-BB1aNLVB
, August 11, 2020
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005847/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
Andersen Consulting får ny samarbejdspartner i Usbekistan22.10.2026 21:34:00 CEST | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for cybersikkerhed og forretningstransformation gennem en samarbejdsaftale med Algoruni, et konsulentfirma med base i Usbekistan. Algoruni rådgiver organisationer om at opbygge cyberrobusthed og håndtere bredere prioriteter inden for ledelse, regulering og bæredygtighed. Virksomheden har base i Tasjkent og tilbyder tjenester inden for cybersikkerhedsstrategi og databeskyttelse, virksomhedsledelse og driftsforbedringer samt ESG-strategi og -rapportering. Fokus er på praktiske løsninger, der er tilpasset den enkelte kundes situation. "Enhver organisation står over for en unik kombination af risici og muligheder. Derfor mener vi, at effektive løsninger skal tage udgangspunkt i virksomhedens konkrete situation," udtalte Alisher Zaynutdinov, administrerende direktør for Algoruni. "Som samarbejdsvirksomhed med Andersen Consulting kan vi kombinere denne tilgang med et bredere netværk af internationale ressourcer og perspektiver, så vi får nye
Andersen Global udvider sine juridiske kompetencer i Argentina gennem samarbejde med MHR22.10.2026 20:20:00 CEST | Pressemeddelelse
Andersen Global styrker sine juridiske kompetencer i Argentina gennem en samarbejdsaftale med Martínez de Hoz & Rueda (MHR) efter integrationen af teamet fra MBP Partners i firmaet. MBP Partners var tidligere et samarbejdsfirma i Andersen Global og arbejdede sammen med organisationens medlemsfirmaer og samarbejdsfirmaer for at bistå klienter med både lokale og internationale forhold. Med integrationen af MBP Partners viderefører den nye samarbejdsaftale mellem Andersen Global og MHR det eksisterende samarbejde og styrker samtidig Andersen Globals juridiske kompetencer i Argentina. MHR er et fullservice advokatfirma, der rådgiver klienter inden for olie og gas, selskabsretlige og finansielle forhold, energi, minedrift, fintech, infrastruktur, teknologi og andre centrale sektorer. Firmaet bistår danske og internationale virksomheder, finansielle institutioner, investeringsfonde, fintechvirksomheder og andre organisationer med komplekse transaktioner, regulatoriske spørgsmål og strategisk
Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 202622.10.2026 19:03:00 CEST | Press release
For Trade and Medical Media Only Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO®(rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic haematopoietic stem cell transplantation (allo-HSCT). The Phase III findings were presented today as a late-breaking oral presentation at IDWeek 2026. The presentation provides additional detail following the top line ReSPECT results announced in April 2026, including further endpoint analyses, the components contributing to fungal-free survival (FFS), pre-specified sensitivity analyses and detailed safety outcomes. The additional analyses were consistent with the previously announced topline findings. ReSPECT was a global, multicentre, randomised, double-blind Phase III study in which 402 patients were randomised to rezafungin and 200 to the standard antimicrobial regimen. As previously announced, the study met its primary endpoi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
